Does size matter in R&D productivity? If not, what does?

被引：61

作者：

Ringel, Michael ^{[1
]}

Tollman, Peter ^{[1
]}

Hersch, Greg ^{[1
]}

Schulze, Ulrik ^{[2
]}

机构：

[1] Boston Consulting Grp Inc, Boston, MA 02109 USA

[2] Boston Consulting Grp Inc, CH-8001 Zurich, Switzerland

来源：

NATURE REVIEWS DRUG DISCOVERY | 2013年 / 12卷 / 12期

关键词：

D O I：

10.1038/nrd4164

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

This analysis of factors that affect the likelihood of success in drug research and development (R&D) indicates that scientific acumen and good judgment — particularly with regard to the early termination of less viable drug candidates — are crucial.

引用

页码：901 / 902

页数：2

共 5 条

[1] The Cost of Biopharmaceutical R&D: Is Biotech Different? [J].

DiMasi, Joseph A. ;

Grabowski, Henry G. .

MANAGERIAL AND DECISION ECONOMICS, 2007, 28 (4-5) :469-479

[2] Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival [J].

Morgan, Paul ;

Van der Graaf, Piet H. ;

Arrowsmith, John ;

Feltner, Doug E. ;

Drummond, Kira S. ;

Wegner, Craig D. ;

Street, Steve D. A. .

DRUG DISCOVERY TODAY, 2012, 17 (9-10) :419-424

[3]

Morieux Y., 2011, HARVARD BUS REV, V86, P136

[4]

Morieux Y, 2011, HARVARD BUS REV, V89, P78

[5]

Pisano G. P., 2006, SCI BUSINESS PROMISE, P1

← 1 →